Financhill
Sell
27

HBIO Quote, Financials, Valuation and Earnings

Last price:
$0.30
Seasonality move :
1.63%
Day range:
$0.34 - $0.38
52-week range:
$0.29 - $3.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.18x
P/B ratio:
1.11x
Volume:
603.4K
Avg. volume:
876.3K
1-year change:
-88.19%
Market cap:
$16.5M
Revenue:
$94.1M
EPS (TTM):
-$1.32

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HBIO
Harvard Bioscience
$19.2M -$0.04 -18.82% -64.29% $3.00
AKYA
Akoya Biosciences
$19.3M -$0.23 -21.86% -14.82% $1.88
AZTA
Azenta
$140.8M $0.07 -13.41% 86.12% $41.60
BNGO
Bionano Genomics
$6.3M -$1.11 -11.23% -97.97% $7.33
BRKR
Bruker
$772.5M $0.44 1.31% 799.94% $55.13
KMTS
Kestra Medical Technologies
$15.7M -$0.53 -- -- $27.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HBIO
Harvard Bioscience
$0.37 $3.00 $16.5M -- $0.00 0% 0.18x
AKYA
Akoya Biosciences
$1.27 $1.88 $63.3M -- $0.00 0% 0.79x
AZTA
Azenta
$27.72 $41.60 $1.3B -- $0.00 0% 2.10x
BNGO
Bionano Genomics
$3.68 $7.33 $12.4M -- $0.00 0% 0.16x
BRKR
Bruker
$37.15 $55.13 $5.6B 71.44x $0.05 0.54% 1.63x
KMTS
Kestra Medical Technologies
$22.52 $27.50 $1.1B -- $0.00 0% 22.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HBIO
Harvard Bioscience
70.79% 2.159 143.69% 0.34x
AKYA
Akoya Biosciences
108.34% 0.070 110.41% 0.36x
AZTA
Azenta
-- 2.222 -- 2.16x
BNGO
Bionano Genomics
21.3% -0.388 150.7% 0.82x
BRKR
Bruker
53.77% 0.828 33.24% 0.66x
KMTS
Kestra Medical Technologies
-- 0.000 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HBIO
Harvard Bioscience
$12.2M -$1.5M -62.88% -103.83% -229.6% $2.3M
AKYA
Akoya Biosciences
$9.9M -$13.3M -52.81% -338.02% -78.8% -$7.4M
AZTA
Azenta
$65.9M -$12.6M -3.48% -3.48% -8.77% $7M
BNGO
Bionano Genomics
$2.9M -$8.5M -112.51% -141.6% -46.62% -$2.8M
BRKR
Bruker
$391.2M $65.7M 2.11% 4.53% 4.77% $39M
KMTS
Kestra Medical Technologies
-- -- -- -- -- --

Harvard Bioscience vs. Competitors

  • Which has Higher Returns HBIO or AKYA?

    Akoya Biosciences has a net margin of -231.19% compared to Harvard Bioscience's net margin of -94.07%. Harvard Bioscience's return on equity of -103.83% beat Akoya Biosciences's return on equity of -338.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
    AKYA
    Akoya Biosciences
    59.33% -$0.32 $70.6M
  • What do Analysts Say About HBIO or AKYA?

    Harvard Bioscience has a consensus price target of $3.00, signalling upside risk potential of 703.64%. On the other hand Akoya Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 48.23%. Given that Harvard Bioscience has higher upside potential than Akoya Biosciences, analysts believe Harvard Bioscience is more attractive than Akoya Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    1 1 0
    AKYA
    Akoya Biosciences
    0 7 0
  • Is HBIO or AKYA More Risky?

    Harvard Bioscience has a beta of 1.441, which suggesting that the stock is 44.128% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HBIO or AKYA?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or AKYA?

    Harvard Bioscience quarterly revenues are $21.8M, which are larger than Akoya Biosciences quarterly revenues of $16.6M. Harvard Bioscience's net income of -$50.3M is lower than Akoya Biosciences's net income of -$15.7M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.18x versus 0.79x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.18x -- $21.8M -$50.3M
    AKYA
    Akoya Biosciences
    0.79x -- $16.6M -$15.7M
  • Which has Higher Returns HBIO or AZTA?

    Azenta has a net margin of -231.19% compared to Harvard Bioscience's net margin of -28.21%. Harvard Bioscience's return on equity of -103.83% beat Azenta's return on equity of -3.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
    AZTA
    Azenta
    45.94% -$0.88 $1.7B
  • What do Analysts Say About HBIO or AZTA?

    Harvard Bioscience has a consensus price target of $3.00, signalling upside risk potential of 703.64%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 50.07%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    1 1 0
    AZTA
    Azenta
    1 5 0
  • Is HBIO or AZTA More Risky?

    Harvard Bioscience has a beta of 1.441, which suggesting that the stock is 44.128% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

  • Which is a Better Dividend Stock HBIO or AZTA?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or AZTA?

    Harvard Bioscience quarterly revenues are $21.8M, which are smaller than Azenta quarterly revenues of $143.4M. Harvard Bioscience's net income of -$50.3M is lower than Azenta's net income of -$40.5M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.18x versus 2.10x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.18x -- $21.8M -$50.3M
    AZTA
    Azenta
    2.10x -- $143.4M -$40.5M
  • Which has Higher Returns HBIO or BNGO?

    Bionano Genomics has a net margin of -231.19% compared to Harvard Bioscience's net margin of -48.04%. Harvard Bioscience's return on equity of -103.83% beat Bionano Genomics's return on equity of -141.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
    BNGO
    Bionano Genomics
    45.5% -$1.15 $61.2M
  • What do Analysts Say About HBIO or BNGO?

    Harvard Bioscience has a consensus price target of $3.00, signalling upside risk potential of 703.64%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 94.52%. Given that Harvard Bioscience has higher upside potential than Bionano Genomics, analysts believe Harvard Bioscience is more attractive than Bionano Genomics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    1 1 0
    BNGO
    Bionano Genomics
    0 2 0
  • Is HBIO or BNGO More Risky?

    Harvard Bioscience has a beta of 1.441, which suggesting that the stock is 44.128% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

  • Which is a Better Dividend Stock HBIO or BNGO?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or BNGO?

    Harvard Bioscience quarterly revenues are $21.8M, which are larger than Bionano Genomics quarterly revenues of $6.5M. Harvard Bioscience's net income of -$50.3M is lower than Bionano Genomics's net income of -$3.1M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.18x versus 0.16x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.18x -- $21.8M -$50.3M
    BNGO
    Bionano Genomics
    0.16x -- $6.5M -$3.1M
  • Which has Higher Returns HBIO or BRKR?

    Bruker has a net margin of -231.19% compared to Harvard Bioscience's net margin of 2.17%. Harvard Bioscience's return on equity of -103.83% beat Bruker's return on equity of 4.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
    BRKR
    Bruker
    48.82% $0.11 $4B
  • What do Analysts Say About HBIO or BRKR?

    Harvard Bioscience has a consensus price target of $3.00, signalling upside risk potential of 703.64%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 48.4%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    1 1 0
    BRKR
    Bruker
    5 8 0
  • Is HBIO or BRKR More Risky?

    Harvard Bioscience has a beta of 1.441, which suggesting that the stock is 44.128% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

  • Which is a Better Dividend Stock HBIO or BRKR?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.54% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HBIO or BRKR?

    Harvard Bioscience quarterly revenues are $21.8M, which are smaller than Bruker quarterly revenues of $801.4M. Harvard Bioscience's net income of -$50.3M is lower than Bruker's net income of $17.4M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bruker's PE ratio is 71.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.18x versus 1.63x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.18x -- $21.8M -$50.3M
    BRKR
    Bruker
    1.63x 71.44x $801.4M $17.4M
  • Which has Higher Returns HBIO or KMTS?

    Kestra Medical Technologies has a net margin of -231.19% compared to Harvard Bioscience's net margin of --. Harvard Bioscience's return on equity of -103.83% beat Kestra Medical Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
    KMTS
    Kestra Medical Technologies
    -- -- --
  • What do Analysts Say About HBIO or KMTS?

    Harvard Bioscience has a consensus price target of $3.00, signalling upside risk potential of 703.64%. On the other hand Kestra Medical Technologies has an analysts' consensus of $27.50 which suggests that it could grow by 22.11%. Given that Harvard Bioscience has higher upside potential than Kestra Medical Technologies, analysts believe Harvard Bioscience is more attractive than Kestra Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    HBIO
    Harvard Bioscience
    1 1 0
    KMTS
    Kestra Medical Technologies
    4 1 0
  • Is HBIO or KMTS More Risky?

    Harvard Bioscience has a beta of 1.441, which suggesting that the stock is 44.128% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HBIO or KMTS?

    Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

  • Which has Better Financial Ratios HBIO or KMTS?

    Harvard Bioscience quarterly revenues are $21.8M, which are larger than Kestra Medical Technologies quarterly revenues of --. Harvard Bioscience's net income of -$50.3M is higher than Kestra Medical Technologies's net income of --. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.18x versus 22.51x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HBIO
    Harvard Bioscience
    0.18x -- $21.8M -$50.3M
    KMTS
    Kestra Medical Technologies
    22.51x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

Buy
88
SMR alert for May 28

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock